Piramal Healthcare’s research strategy is to rapidly discover, optimize and develop novel small molecule drugs to meet important unmet clinical needs for the target indications of cancer, metabolic disorders, inflammation, and infectious diseases.
Piramal Healthcare Limited (PHL) aims to be the first Indian company to discover, develop and launch its own NCE in the global market.
The key elements of our strategy include:
- Innovative sourcing of leads: By leveraging India’s bio-diversity and vast pool of knowledge in traditional medicinal systems, and through partnerships with universities, institutes and pharmaceutical companies
- Scientific excellence: PHL has assembled a world class scientific team and established a dominant position in drug discovery and development through its proprietary molecules and technologies
- State-of-the art infrastructure: To enable scientists to produce high-quality, world-class science, the Research Centre provides them with the best equipment, facilities and technology, and a nurturing work environment
- Major thrust on oncology drug development
- Leverage partnerships to expand metabolic disorder pipeline
- Pursue partnerships for inflammation & infectious disease programs
- Establish seamless capabilities from discovery through preclinical and clinical development, up to launch
- Widen the clinical pipeline through in-licensing
- Seek partnerships and collaborations for late stage development and commercialization